蓝帆医疗助力百心安RDN系统获得新加坡创新准入资格，为亚太高血压患者带来中国创新方案

动脉网2025-09-26

蓝帆医疗心脑血管事业部主体蓝帆柏盛与百心安旗下安通医疗就铂睿时Iberis™多极肾动脉射频消融（RDN）系统展开代理合作，此前已在德国、西班牙、意大利等国完成商业化布局，且德国、法国已将其纳入医保。近日，该系统通过新加坡卫生科学局审核，获批用于新加坡临床治疗，推动其亚太市场合规化进程，为当地高血压患者提供新治疗选择。目前，蓝帆柏盛海外团队已启动该系统在新加坡及亚太地区的全流程注册，将提供一站式服务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2570854663?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-26 14:36","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2570854663","market":"hk","top_or_hot":-1,"title":"蓝帆医疗助力百心安RDN系统获得新加坡创新准入资格，为亚太高血压患者带来中国创新方案","media":"动脉网","content":"<div>\n<p>蓝帆医疗心脑血管事业部主体蓝帆柏盛与百心安旗下安通医疗就铂睿时Iberis™多极肾动脉射频消融（RDN）系统展开代理合作，此前已在德国、西班牙、意大利等国完成商业化布局，且德国、法国已将其纳入医保。近日，该系统通过新加坡卫生科学局审核，获批用于新加坡临床治疗，推动其亚太市场合规化进程，为当地高血压患者提供新治疗选择。目前，蓝帆柏盛海外团队已启动该系统在新加坡及亚太地区的全流程注册，将提供一站式服务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926150533a69f6618&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>蓝帆医疗助力百心安RDN系统获得新加坡创新准入资格，为亚太高血压患者带来中国创新方案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n蓝帆医疗助力百心安RDN系统获得新加坡创新准入资格，为亚太高血压患者带来中国创新方案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-26 14:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926150533a69f6618&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>蓝帆医疗心脑血管事业部主体蓝帆柏盛与百心安旗下安通医疗就铂睿时Iberis™多极肾动脉射频消融（RDN）系统展开代理合作，此前已在德国、西班牙、意大利等国完成商业化布局，且德国、法国已将其纳入医保。近日，该系统通过新加坡卫生科学局审核，获批用于新加坡临床治疗，推动其亚太市场合规化进程，为当地高血压患者提供新治疗选择。目前，蓝帆柏盛海外团队已启动该系统在新加坡及亚太地区的全流程注册，将提供一站式服务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926150533a69f6618&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926150533a69f6618&s=b","article_id":"2570854663","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926150533a69f6618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2570854663","pubTimestamp":1758868560,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"蓝帆医疗心脑血管事业部主体蓝帆柏盛与百心安旗下安通医疗就铂睿时Iberis™多极肾动脉射频消融（RDN）系统展开代理合作，此前已在德国、西班牙、意大利等国完成商业化布局，且德国、法国已将其纳入医保。近日，该系统通过新加坡卫生科学局审核，获批用于新加坡临床治疗，推动其亚太市场合规化进程，为当地高血压患者提供新治疗选择。目前，蓝帆柏盛海外团队已启动该系统在新加坡及亚太地区的全流程注册，将提供一站式服务，加速产品上市。根据新加坡HSA审批文件，该系统全链条合规，明确用于高血压介入治疗，并强化了安全监管要求。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"translate_title":"Blue Sail Medical helps Baixinan RDN system obtain Singapore's innovative access qualification, bringing Chinese innovative solutions to hypertensive patients in Asia-Pacific","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":0.9},"content_text":"蓝帆医疗心脑血管事业部主体蓝帆柏盛与百心安旗下安通医疗就铂睿时Iberis™多极肾动脉射频消融（RDN）系统展开代理合作，此前已在德国、西班牙、意大利等国完成商业化布局，且德国、法国已将其纳入医保。近日，该系统通过新加坡卫生科学局审核，获批用于新加坡临床治疗，推动其亚太市场合规化进程，为当地高血压患者提供新治疗选择。目前，蓝帆柏盛海外团队已启动该系统在新加坡及亚太地区的全流程注册，将提供一站式服务，加速产品上市。根据新加坡HSA审批文件，该系统全链条合规，明确用于高血压介入治疗，并强化了安全监管要求。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570854663","isCrawlerRequest":true}